Voya Beats Its Peers Into Earnings as Analysts Cool on the Stock

VOYA gained 3.0% over the past week to close at $99.42, outpacing the median of its closest correlated peers, where CRBG, EQH, and JXN each added between 2.0% and 3.6%. That puts Voya at the stronger end of the group going into its November 3 print, a reversal from the modest underperformance flagged in last week's preview when the stock was at $98.39.

Options positioning remains tilted toward calls rather than protection. The put/call ratio ticked up to 0.27 from the 0.22 reading earlier in the week but is still below its 20-day average of 0.28, roughly in line with recent norms and far from the defensive territory suggested by the 52-week high of 1.70. The borrow market is similarly relaxed: availability runs at 3,691%, meaning the pool of shares available to lend dwarfs anything currently borrowed. Borrowing costs have risen 16% over the past week to 0.49%, but the absolute level remains very low. Short interest at 3.8% of the free float has climbed roughly 20% over the past month in share terms, yet the position has barely moved in the final few days before the print, down fractionally on the week.

The analyst community has grown more cautious even as the stock has held up. Keefe, Bruyette & Woods cut Voya to Market Perform from Outperform in the 19 days before the print, lowering its target to $108 from $110. JP Morgan trimmed to $105 from $109 while staying Neutral. Wells Fargo also cut its target, to $102 from $104. On the other side, Barclays lifted its target to $109 from $105 and UBS raised to $127 from $125, both maintaining positive ratings. The consensus mean price target is $107.83 against a current price of $99.42, implying about 8% potential upside. The debate is familiar: those who see value point to Voya's capital-light fee model, 90%-plus free cash flow conversion, and active buybacks, including $150 million of repurchases in Q1 2026. Those who are more cautious focus on execution risk in the Stop Loss business, ongoing uncertainty about the Benefitfocus acquisition, and a valuation that has sat at a persistent discount to peers, currently around 9x forward earnings, despite a strong year-to-date run.

Insider activity over the past 90 days has been one-sided on net, with sales outweighing purchases. The largest recent transaction was a pair of open-market sales by Keshavan Santhosh in late August, totalling roughly $3.5 million across two transactions, both executed under a pre-arranged 10b5-1 plan. A smaller planned sale of around $200,500 was filed by Trevor Ogle on October 26. Planned sales carry less informational weight than discretionary ones, but the net 90-day position, approximately $3.7 million sold, adds a mild cautionary note to the otherwise constructive options and price-action picture. T. Rowe Price added 631,723 shares through the end of September, now at 7.5% of shares, while Wellington Management's 13G/A filing from August showed its stake had dropped to 4.3% from 6.6%, a notable reduction from one of the more active institutional names on the register.

The print will test whether Voya's stop-loss repricing is progressing as management has signalled, and whether investment management organic growth can hold the 2%-plus rate that bulls are counting on to justify a re-rating toward peer multiples.